key: cord-0928486-qf7k9ked
authors: Zhufeng, Chen; Wanju, Xu; Wanshan, Ma; Xiaohong, Shi; Shuomin, Li; Mingju, Hao; Yuanxun, Fang; Li, Zhang
title: Clinical laboratory evaluation of COVID-19
date: 2021-04-30
journal: Clin Chim Acta
DOI: 10.1016/j.cca.2021.04.022
sha: b3f0dfe1085fdcfc55853e0fc11b786309e23ef8
doc_id: 928486
cord_uid: qf7k9ked

COVID-19, caused by SARS-CoV-2, is a highly infectious disease, and clinical laboratory detection has played important roles in its diagnosis and in evaluating progression of the disease. Nucleic acid amplification testing or gene sequencing can serve as pathogenic evidence of COVID-19 diagnosing for clinically suspected cases, and dynamic monitoring of specific antibodies (IgM, IgA, and IgG) is an effective complement for false-negative detection of SARS-CoV-2 nucleic acid. Antigen tests to identify SARS-CoV-2 are recommended in the first week of infection, which is associated with high viral loads. Additionally, many clinical laboratory indicators are abnormal as the disease evolves. For example, from moderate to severe and critical cases, leukocytes, neutrophils, and the neutrophil-lymphocyte ratio increase; conversely, lymphocytes decrease progressively but are over activated. LDH, AST, ALT, CK, high-sensitivity troponin I, and urea also increase progressively, and increased D-dimer is an indicator of severe disease and an independent risk factor for death. Severe infection leads to aggravation of inflammation. Inflammatory biomarkers and cytokines, such as CRP, SAA, ferritin, IL-6, and TNF-α, increased gradually. High-risk COVID-19 patients with severe disease, such as the elderly and those with underlying diseases (cardiovascular disease, diabetes, chronic respiratory disease, hypertension, obesity, and cancer), should be monitored dynamically, which will be helpful as an early warning of serious diseases.

Coronavirus disease 2019 (COVID-19), which is caused by SARS-CoV-2, is a severe acute respiratory infectious disease that has led to a global pandemic and brought a major threat to human life and health. Common clinical symptoms include fever, cough, dyspnea, myalgia, and fatigue; less common symptoms are expectoration, headache, hemoptysis, diarrhea, and loss of taste and smell ［1-3］.

The main complications included sepsis, respiratory failure acute respiratory distress syndrome (ARDS), acute cardiac injury, acute kidney injury, arrhythmia, gut and liver function abnormalities, shock, and secondary infection ［ 1, 2, 4, 5 ］ . In children, special sporadic symptoms are features of severe Kawasaki-like disease［6-9］.

Associated biomarkers include hematologic, biochemical, coagulation-fibrinolysis system, and inflammatory indicators. Furthermore, SARS-CoV-2 nucleic acid, antigen, and antibody detection can contribute to an etiological or serological diagnosis of SARS-CoV-2 infection, so clinical laboratory detection has played important roles in the COVID-19 pandemic. This review aims to report the current knowledge regarding clinical laboratory biomarkers of COVID-19, focusing on the diagnosis, evaluation of progression, and early warning of severe disease.

Coronaviruses are enveloped viruses containing a positive-sense, single-stranded RNA genome and characteristic crown-like spikes on their surfaces. Coronaviruses are members of the Coronavirinae subfamily of the Coronaviridae family. This subfamily consists of four genera: alphacoronavirus, betacoronavirus, gammacoronavirus, and deltacoronavirus ［ 10 ］ . According to whole-genome sequencing, SARS-CoV-2 belongs to a new type of betacoronavirus ［ 11, 12 ］ . SARS-CoV-2 shares 79.6% and 51.8% sequence identity with severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome (MERS-CoV), respectively ［ 13 ］ . In addition, SARS-CoV-2 is 96% identical at the whole-genome level to a bat coronavirus and 80-98% identical to a Malayan pangolin coronavirus［14, 15］. The origin of SARS-CoV-2 remains to be determined. SARS-CoV, MERS-CoV, and SARS-CoV-2 are all betacoronaviruses.

These three coronaviruses can cause lower respiratory tract infections and serious inflammation.

The basic mechanism of SARS-CoV-2 infection involves viral binding to the membrane-bound form of angiotensin-converting enzyme 2 (ACE2) ［ 12, 14 ］ .

Although sharing a close relationship with SARS-CoV, the RBD of SARS-CoV-2 differs in several key amino acids and has a stronger binding affinity for ACE2, possibly explaining its greater pathogenicity ［ 16 ］ . ACE2, a glycoprotein and metalloprotease, exists in membrane-bound and soluble forms ［ 17 ］ . The membrane-bound form contains a transmembrane domain that anchors its extracellular domain to the plasma membrane; the N-terminal domain is cleaved and secreted into the blood circulation in a soluble free form.

Cell entry of SARS-CoV-2 depends on binding of the S protein to ACE2, after which the S protein is primed by a host cell protease. Transmembrane protease serine type 2 (TMPRSS2), belonging to the type II transmembrane serine protease family, can cleave the coronavirus spike (S) protein［18-21］. The S protein consists of two subunits: a globular S1 domain at the N-terminal region and a membrane-proximal S2 domain. SARS-CoV-2 utilizes a receptor-binding domain in the S1 domain to bind to ACE2, triggering cleavage of S1 and S2 by TMPRSS2 and membrane fusion for viral entry ［ 22, 23 ］ . As receptors and mediators of virus entry, the routes and target organs of SARS-CoV-2 infection may depend on the expression and distribution of ACE2 and TMPRSS2 ［ 24, 25 ］ . In the airway, ACE2 and TMPRSS2 were both expressed in multiple epithelial cell types, including ciliated cells, secretory cells, and alveolar epithelial type II cells of respiratory organs. Among these cells, the highest expression has been detected in secretory cells and ciliated cells of nasal tissue［25］.

In addition to its expression in the respiratory system, ACE2 and TMPRSS2 are coexpressed in the cornea, ileum, heart, kidney, colon, esophagus, brain, gallbladder, common bile duct, and testis ［24-26 ］, with high coexpression in the gallbladder, ileum, and colon ［ 25 ］ . This diverse expression distribution suggests that SARS-CoV-2 infection can not only cause injury to the respiratory system but also to other organs.

The pathophysiological features of severe COVID-19 are dominated by acute lung lesions with diffuse alveolar damage, microvascular thrombosis, and inflammatory infiltrates ［ 27 ］ . Increasing evidence suggests that tissue damage in COVID-19 is partly mediated by an excessive immune response［28, 29］. Indeed, virus-mediated destruction of lung cells induces a wave of local inflammation involving increased secretion of proinflammatory cytokines and chemokines such as IP-10, IL-6, MCP1, and IFN-γ ［ 1, 30 ］ , and localized release of cytokines drives recruitment of macrophages, monocytes, and T lymphocytes to the site of infection, promoting a pro-inflammatory feedback loop mediated by IFN-γ ［ 31, 32 ］ . In particular, the massive release of cytokines in response to viral infection can result in a cytokine storm and sepsis-like symptoms that lead to multiorgan failure and even death［30］.

The full-length genome of SARS-CoV-2 is approximately 30 kb long, with an open-reading frame (ORF) at the 5' terminus. The viral genome consists of six major ORFs accounting for approximately two-thirds of the whole genome. The 3' terminal gene encodes 4 structural proteins and RNA-dependent RNA polymerase (RdRp).

The structural proteins include the E gene encoding the envelope protein, M gene encoding the membrane protein, N gene encoding the nucleocapsid protein, and S gene encoding the spike-like glycoprotein ［ 14 ］ . Rapid and accurate detection of COVID-19 is crucial to control outbreaks. Studies have shown that nucleic acid technologies are generally more accurate than CT scans and serological tests for 8 definitive diagnosis of COVID-19, as they can target and identify the specific gene sequence of SARS-CoV-2. To date, there are two main methods of SARS-CoV-2 nucleic acid detection: gene sequencing and nucleic acid amplification testing (NAAT). Each can provide evidence of an etiological diagnosis［33］.

High-throughput sequencing/metagenomic next-generation sequencing (mNGS), which is based on second-generation sequencing technology, does not require culturing, with no preference for pathogen detection. Due to the advantages of mNGS for new pathogen detection, Chinese scientists completed the identification and analysis of the SARS-CoV-2 genome in only five days, which became a key link in epidemic control ［34］. Clinical specimens used for SARS-CoV-2 gene sequencing include nasopharynx swabs, sputum, and bronchoalveolar lavage fluid (BLF). The protocol of mNGS is typically divided into five steps: nucleic acid extraction, library construction, gene sequencing, biological information analysis, and interpretation. If the nucleic acid sequence is highly homologous with that of SARS-CoV-2, then the case can be confirmed. The limitations of gene sequencing include a long turn-around time, complex procedure, inadequate standardization, and high personnel qualification criteria regarding detection and data analysis［35］. Currently, DNA sequencing has been carried out only in some medical laboratories (laboratory in a hospital or independent medical laboratory).

Gene sequencing is not only used for etiological diagnosis of COVID-19, but it can also provide information such as pathogen abundance and variation ［ 36 ］ .

According to the characteristics of the SARS-CoV-2 genetic cluster, scientists can trace the source of infection, evaluate virus variation, and carry out epidemiological The rate of spread of variants can be greater than 70% compared to the normal SARS-CoV-2 virus, but the variants were not found to cause more severe respiratory illness［39］.

Molecular NAAT methods are the standard confirmation tests for SARS-CoV-2 infections by the WHO［40］. Among NAAT methods, qRT-PCR is a common and routine approach. In fact, it can be used to detect a variety of clinical specimens, including BLF, fiber bronchoscope brush biopsies, sputum, nasal swabs, pharyngeal swabs, feces, and blood［1, 41, 42］. Kits may include one, two, or three specific primer pairs for SARS-CoV-2 nucleic acids. Specific primers and TaqMan probes are designed according to evolutionarily conserved ORF1ab, ORF1b-nsp14, RdRp1, RdRp2, spike (S), nucleocapsid (N) , and envelope (E) ［ 43-49 ］ . If two SARS-CoV-2 targets meet or exceed the threshold, the result is positive. If only one target is detected, then the sample is recollected and tested; if a positive reaction still appears, the sample will be classified as positive. No detection of any SARS-CoV-2 target is considered a negative result. When the test results are in the "gray zone" (near the thresholds or weakly positive), using another brand kit or resampling and testing again is recommended［50］. The average period of qRT-PCR detection is 3～ 5 hours. The qRT-PCR method can be used for a quick screen of a large number of samples from the requested population.

In addition to routine qRT-PCR for confirmation, other RT-PCR assays have been developed for the identification of SARS-CoV-2. A real-time nested RT-PCR assay has been developed for detecting low-copy-number SARS-CoV-2 with high sensitivity ［ 51, 52 ］ . However, nested RT-PCR can cause laboratory cross-contamination, which may lead to false-positive results［53］. Droplet digital PCR (ddPCR) has also been shown to increase the lower LOD, sensitivity, and accuracy in detecting SARS-CoV-2 ［ 54, 55 ］ . Overall, it is important to ensure result consistency among different molecular laboratories.

Nevertheless, "false negatives" of SARS-CoV-2 nucleic acid detection by the qRT-PCR method have been reported. In some cases, a positive result appeared after multiple sampling tests. Nasopharyngeal or throat swabs may be negative many times, with positive results eventually detected in sputum specimens or respiratory lavage fluid samples ［ 56-58 ］ . Several factors may affect the nucleic acid detection rate.

Because the distribution of viral load varies among clinical samples, nucleic acid detection rates are usually different. For example, BLF specimens show the highest positivity rates (93%), followed by rectal swabs (87.8%), sputum (72%), nasal swabs (63%), fibrobronchoscope brush biopsy (46%), nasopharyngeal swabs (45.5%), pharyngeal swabs (32%), and feces (29%); blood has the lowest detection rate (1%)

［41］. In general, lower respiratory tract specimens, such as BLF and sputum, have higher detection rates and are the recommended clinical samples. However, collection of BLF samples is somewhat invasive, and most patients have dry cough without sputum, which limits the use of BLF and sputum samples［59, 60］. Nasopharyngeal swabs, a widely used specimen, are easy to collect but have a relatively low detection rate. Furthermore, RNA fragment damage occurring during the process of SARS-CoV-2 nucleic acid extraction may cause nucleic acid loss and decrease the detection rate. Novel mutant strains of SARS-CoV-2 may also cause false negatives.

For example, spike gene target failure for the qRT-PCR assay (ThermoFisher) was reported when testing viruses with H69-V70 spike deletion in France ［ 61 ］ .In the early stage of the COVID-19 epidemic, a large amount of PCR tests was produced, though there were some defects, such as contamination of primers/probes of SARS-CoV-2 targets ［ 62 ］ . Furthermore, qRT-PCR technology requires professionally trained staff. Nonetheless, various measures can improve the nucleic acid detection rate, such as multiple sampling tests, adding or altering target genes according to virus variation, valid kit evaluation, external quality assessment, and laboratory staff training.

Another important detection method based on NAAT is reverse transcription loop-mediated isothermal amplification (RT-LAMP) ［ 63-65 ］ , one of the point-of-care tests (POCTs) for nucleic acid amplification. RT-LAMP was developed as a rapid, accurate, and reliable technique to amplify a target sequence at a single reaction temperature rather than the thermal cycling needed for qRT-PCR ［ 66 ］ .

Indeed, RT-LAMP is performed in one step at 63 °C isothermal conditions, and by targeting the ORF1ab, spike (S), envelope (E), or/and N genes of SARS-CoV-2, results are obtained within 15-40 minutes ［ 63-65, 67, 68 ］ . The advantage of the LAMP method is that the amount of DNA produced is much higher than that in qRT-PCR, and a positive test result can even be seen visually without another machine. Two studies have shown evidence that RT-LAMP methods have sensitivity ranging from 89.9% to 91.4% compared to qRT-PCR when targeting the ORF1ab and nucleocapsid (N) genes［69, 70］. Additionally, the detection limit of RT-LAMP is 100-500 copies/mL, which is almost the same as that of qRT-PCR kits ［ 64, 65 ］ .

Importantly, studies have shown that RT-LAMP analysis is more specific than qRT-PCR because it uses five or six primers to identify different regions on the target DNA ［ 64, 65 ］ . Hence, the RT-LAMP method has wide application in SARS-CoV-2 diagnosis due to its relatively simple operation and low technical requirements for laboratory staff. 

Although nucleotide acid-based methods are recommended for assessing SARS-CoV-2 infection, they have a relatively low detection rate［79］. Therefore, many experts suggest using specific antibody detection as a supplement for nucleic Overall, the seroconversion time differs with the type of antibodies; the first is total antibodies, followed by IgM and IgG. In a study based on 173 COVID-19 patients, the median seroconversion for total antibodies, IgM, and IgG directed against an RBD-specific protein occurred on day 11, day 12, and day 14, respectively.

The detection rate of antibodies was <40% among patients within one week after onset and rapidly increased to 100.0% (total antibody), 94.3% (IgM), and 79.8% (IgG) after two weeks. In contrast, the detection rate of RNA decreased from 66.7% before day 7 to 45.5% during days 15-39［83］. Therefore, the detection rate of antibodies is lower than that of nucleic acid in the first week but gradually increases; in particular, the detection rate of total antibodies was up to 100% two weeks later. In contrast, the detection rate of nucleic acids decreases gradually after one week. Therefore, combined detection of antibodies and nucleic acids has complementarity and improves the detection rate. IgG and IgM antibodies are typically present at different times, and IgG antibodies last longer. When the SARS-CoV-2 nucleic acid test becomes negative, the positivity rate of IgM decreases from 88% to 53%, whereas that for IgG changes slightly［84］. Therefore, in addition to utility in diagnosis, the rapid cell-based biosensor for detecting the SARS-CoV-2 S1 protein, providing results in only 3 minutes, with a detection limit of 1 fg/mL［94］. Therefore, further investigations are needed to explore the best antigen targets and detection methods.

Because of the limitations of antigen detection and the large variation between different reports, it may be necessary to confirm a rapid antigen test result with a nucleic acid test, especially when the result of the antigen test is inconsistent with the clinical manifestations ［ 90 ］ . The minimum performance requirements of SARS-CoV-2 Ag-RDTs are ≥80% sensitivity and ≥97% specificity compared to the NAAT reference assay, and they can be used to confirm SARS-CoV-2 infection ［ 95 ］ . Nevertheless, the use of Ag-RDTs is not recommended in settings or populations with a low expected prevalence of COVID-19［91］.

Laboratory biomarkers related to the diagnosis of COVID-19 include nucleic acid, antibody, and antigen detection. NAAT, such as qRT-PCR, is the most commonly used and preferred method, though antibody detection is more advantageous in the recovery period. The antigen detection rate is high in the early stage. The characteristics of each biomarker are summarized in Table 1 , including main specimens, advantages, and disadvantages.

Clinical criteria for COVID-19 generally include related respiratory system symptoms, typical radiological signs, a normal or decreased WBC/lymphocyte count in the early stage, anorexia/nausea/vomiting, diarrhea, and an altered mental status, among others［33, 96］. When the patients meet the clinical and epidemiological criteria of COVID-19, the cases are clinically suspected cases. According to the diagnosis and treatment guide of COVID-19 from the WHO and China［33, 40］, nucleic acid testing is recommended first for a clinically suspected case to confirm the disease. The detailed laboratory diagnosis process is illustrated in Figure 1 

COVID-19 is generally divided into mild, moderate, severe, and critical classifications based on respiratory symptoms, pulmonary imaging, and the need for mechanical ventilation assistance［33］. Statistical data released by the WHO show that approximately 82% of COVID-19 cases are mild, 15% severe and 3% critical. In total, 19.6% of all patients may develop acute respiratory distress syndrome (ARDS), though the incidence of ARDS increases to 50% in severe and critical patients. The population at high risk for severe and critical illness includes elderly individuals over 65 years old, immunodeficient patients, late-pregnancy and perinatal women, heavy smokers, and those with underlying diseases. Underlying diseases mainly include cardiovascular disease, diabetes, chronic respiratory disease, hypertension, chronic liver and kidney disease, obesity, and cancer［2, 33, 98, 99］. These high-risk factors are often associated with adverse outcomes and more mortality. As the disease evolves from moderate to severe and critical, SARS-CoV-2 infection leads to many abnormal changes in laboratory biomarkers, generally including hematologic, biochemical, coagulation-fibrinolysis system, and inflammatory biomarkers.

The WBC count is normal or decreased in approximately 80% of patients, and 72.3% of the patients develop lymphocytopenia, consistent with the basic characteristics of viral infection［100］. However, the WBC count in severe cases is higher than that in moderate cases, with critical cases being highest. Compared with moderate cases, patients with severe COVID-19 have a significantly reduced lymphocyte count［101, Decreased platelet count may indicate platelet consumption from thrombus formation, whereas an increased platelet count suggests stimulated production of megakaryocytes and increased platelet synthesis due to inflammation［113］.

Overall, obvious changes in hematologic biomarkers include continued lymphocytopenia and a decrease in monocytes, basophils, and eosinophils but a significant increase in leukocytes, neutrophils, and NLR in severe and critical COVID-19. These basic biomarkers can be helpful for early warning and identification of severe disease［114, 115］.

Many biochemical markers are abnormal in COVID-19 patients because of corresponding organ damage, especially cardiac, liver, and kidney injuries. In the analysis of a large number of 1099 COVID-19 inpatients, the proportion of elevated biochemical markers gradually increased from nonsevere to severe to critical cases, and the most obvious change was for LDH, followed by AST, ALT, CK, and creatinine ［ 106 ］ . Chen et al. also observed markedly higher concentrations of LDH, ALT, AST, creatinine, CK, cardiac troponin I, and N-terminal pro-brain natriuretic peptide in nonsurvivors than in recovered patients［116］. Levels of LDH, hypersensitivity myocardial troponin I, urea, and creatinine increase progressively in fatal cases from onset［2, 4］, and hypoalbuminemia often occurs in severe cases［1, 105］. Other biochemical markers, such as the oxygenation index and lactic acid, are reported to be associated with severe illness. For example, compared with surviving COVID-19 patients with cardiovascular disease, the oxygenation index was lower and lactic acid significantly higher in nonsurvivors ［ 117 ］ . Therefore, continuous elevation of these common biochemical markers, such as LDH, CK, AST, ALT, urea, and creatinine, indicates a high risk of severe illness and poor prognosis.

Due to excessive inflammation and hypoxia, some COVID-19 patients present coagulation and fibrinolysis abnormalities, with increased thrombotic complications such as pulmonary embolism (PE) and disseminated intravascular coagulation (DIC) ［ 2, 4, 106, 118］ . Furthermore, coagulopathy in COVID-19 patients is associated with an increased risk of death ［ 119 ］ . Accordingly, abnormal coagulation and fibrinolysis biomarkers are associated with a poor prognosis in COVID-19 patients.

The most typical finding is an increased D-dimer concentration. In a retrospective, clinical study, of nonsevere, severe, and critical COVID-19, the elevated proportion of D-dimer was found to gradually increase［106］, and the elevated proportions of D-dimer were higher in nonsurvivors than survivors ［ 2, 4 ］ . Moreover, D-dimer level greater than 1 μg/mL is an independent risk factor for death among inpatients ［2, 4］, and increased D-dimer is predictive of coagulation-associated complications, critical illness, and death during hospitalization［120］.

In addition to increases in D-dimer, other coagulation and fibrinolysis biomarkers are abnormal. For example, markedly elevated FDP was detected in nonsurvivors; prolonged APTT and PT were also observed in nonsurvivors compared to survivors on admission［119］. Furthermore, fibrinogen is higher in patients with than in those without thrombotic complications ［ 120 ］ . In severe COVID-19, expression of tissue factor and secretion of von Willebrand factor cause endothelial cell injury. Free thrombin activates platelets and stimulates fibrinolysis, possibly leading to high concentrations of D-dimer, FDP and fibrinogen and prolonged APTT/PT. Among these biomarkers, changes in D-dimer are the most obvious. These changes suggest coagulation activation and secondary hyperfibrinolysis conditions in severe cases［119, 121］.

Most COVID-19 patients exhibit mild symptoms at the early stage; later, the condition of a small number of cases unexpectedly worsens and even leads to death, which is partly associated with the "inflammatory storm" or "cytokine storm syndrome When SARS-CoV-2 infection caused an "inflammatory storm", not only associated cytokines rise sharply, but some inflammatory biomarkers also increase, such as CRP, serum ferritin, SAA, and PCT. Compared with the moderate COVID-19 group, levels of ferritin, CRP, SAA, and PCT were significantly increased in severe and critical groups［101, 104, 123］. The specificity and sensitivity of the combined detection of CRP, SAA, and WBC can reach 78.67% and 100%, respectively, in severe and critical cases［102］. Levels of CRP, IL-6, SAA and PCT in serum were found to be in the following order: critical group> severe group> moderate group> mild group. These indicators were noted to increase significantly in the nonsurvival group compared with the survival group［124, 125］. Accordingly, increases in these inflammatory biomarkers indicate a high risk of severe illness and poor prognosis.

The RAS plays an important role in regulating electrolyte balance and blood pressure via two pathways: the ACE/Ang II/AT1R pathway and the ACE2/Ang (1-7)/Mas receptor pathway ［ 126 ］ . To maintain normal function, the activity of the two axes is in a dynamic equilibrium state. The main roles of ACE2 are to physiologically counterbalance angiotensin-converting enzyme (ACE) and regulate angiotensin II (Ang II). ACE2 converts Ang I to Ang-(1-9), as well as Ang II to Ang-(1-7), which is protective in cardiovascular tissue［127］. In general, higher levels of plasma ACE2 are associated with a greater risk of death, stroke, myocardial infarction, diabetes, and heart failure［130］, and elevated plasma ACE2 is likely an insufficient compensatory response to overactive RAS activity rather than a cause［131, 132］. Additionally, membrane-bound ACE2 may exhibit abnormal shedding in SARS-CoV-2 infection; thus, levels of plasma ACE2 might be elevated. However, there are no data to date regarding levels of ACE2 in plasma from COVID-19 patients. Therefore, we are unable to determine a correlation between SARS-CoV-2 infection and related changes in RAS biomarker concentrations.

The change trends of these biomarkers related to disease progression and prognosis in nonsevere to severe and critical cases and between survivors and nonsurvivors are summarized in Table 2 .

Laboratory detection has played irreplaceable roles in the diagnosis and evaluation of COVID-19. SARS-CoV-2 nucleic acid and specific antibodies can be used to confirm and exclude suspected cases. A suspected case can be confirmed if etiological or serological evidence is present. If both nucleic acids and antibodies against SARS-CoV-2 are negative, SARS-CoV-2 infection can be ruled out.

SARS-CoV-2 nucleic acid detection can also be used to confirm asymptomatic infections. Overall, the sensitivity of SARS-CoV-2 IgG is higher than that of IgM, but the specificity of IgM is better. If NAAT is unavailable or limited in high expected prevalence of COVID-19, Ag-RDTs are generally recommended for use in the early stages of SARS-CoV-2 infection. Regardless, nucleic acid detection, especially molecular NAAT methods such as qRT-PCR, is the preferred and standard approach for the diagnosis of COVID-19.

In addition to COVID-19 diagnosis, laboratory tests are also used for assessing the progression and prognosis of the disease. Significant changes in many biomarkers, such as decreased lymphocytes, increased D-dimer, and elevated biochemical and inflammatory markers, are found in patients with severe COVID-19. Inflammation biomarkers mainly include C-reactive protein, serum amyloid A, iron proteins, and procalcitonin. Elevated LDH, AST, CK, high-sensitivity troponin I, and urea are common biochemical markers in patients with severe illness. When these biomarkers continue to rise dynamically, they serve as an early warning signal of severe disease and poor prognosis. In addition, detection of cytokines, such as IL-2, IL-6, IL-7, IL-10, IP10, and TNF-α, is recommended to assess whether there is an excessive immune response. More attention needs to be paid to COVID-19 patients with a high risk of severe illness. When warning signals of severe illness appear, appropriate treatment measures should be taken in a timely manner to reduce the occurrence of severe disease. Laboratory detection will provide better assistance for the early diagnosis of COVID-19 and for assessing disease progression.

This work was supported by grants from the National Nature Science Foundation 

The authors report no conflict of interest. ii: Nucleic acid detection generally includes two methods: gene sequencing and NAAT. Any one of them can be used for the detection of SARS-CoV-2.

iii: Specific antibody (IgM and IgG) detection is recommended in both the acute phase and convalescent phase to observe seroconversion or an increase in antibody titer.

ⅳ: Exclusion of suspected cases needs to meet criteria for SARS-CoV-2 nucleic acid and antibody negativity.

With high expected prevalence, the WHO recommends Ag-RDTs to identify SARS-CoV-2 infection in the early stage when NAAT is unavailable or not sufficient. Antigen tests to identify SARS-CoV-2 infection are recommended in the early stages with high viral loads.

Dynamic detection of some biomarkers such as lymphocytes, LDH, AST, D-dimer, CRP, SAA, and IL-6 will be helpful as an early warning of serious diseases, especially in high-risk patients of severe and critical illness.

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study

Kawasaki-like disease: emerging complication during the COVID-19 pandemic

COVID-19 and Kawasaki Disease: Novel Virus and Novel Case

Hyperinflammatory shock in children during COVID-19 pandemic

Origin and evolution of pathogenic coronaviruses

China Novel Coronavirus I, Research T. A Novel Coronavirus from Patients with Pneumonia in China

Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins

Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China

A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9

TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein

TMPRSS2: A potential target for treatment of influenza virus and coronavirus infections

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

ACE2, TMPRSS2 distribution and extrapulmonary organ injury in patients with COVID-19

SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes

Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection

Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Longitudinal analyses reveal immunological misfiring in severe COVID-19

Clinical characteristics of 82 cases of death from COVID-19

The trinity of COVID-19: immunity, inflammation and intervention

［33］National Health Commission of the People's Republic of China & National Administration of Traditional Chinese Medicine. Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia

Advantages and challenges of metagenomics next-generation sequencing (mNGS) in the detection of 2019 novel coronavirus

RNA based mNGS approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak

The establishment of reference sequence for SARS-CoV-2 and variation analysis

SARS-CoV-2 viral spike G614 mutation exhibits higher case fatality rate

The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem

Diagnostic testing for SARS-CoV-2. Interim guidance

Detection of SARS-CoV-2 in Different Types of Clinical Specimens

Analysis of 8 274 cases of novel coronavirus nucleic acid detection and co•infection in Wuhan

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

［45］China National Institute for Viral Disease Control and Prevention: Beijing. Specific Primers and Probes for Detection 2019 Novel Coronavirus

Real-time RT-PCR assays for the detection of SARS-CoV-2

Detection of Second Case of 2019-nCoV Infection in Japan

sequencing-pro tocols-for-2019-ncov--national-institute-of-infectious-diseases-japan. ［48］School of Public Health, Hong Kong University. Detection of 2019 Novel Coronavirus (2019-nCoV) in Suspected Human Cases by

cor onavirus-in-suspected-human-cases-20200117. ［49］Department of Medical Sciences, Ministry of Public Health, Thailand. Diagnostic Detection of Novel Coronavirus

foll owed-by-sequencing-for-detection-of-ncov-rirl-nat-inst-health-t.pdf ［50］Chinese Association of Laboratory Medicine. The Expert Consensus of Novel Coronavirus 2019 nucleic acid detection

Development of Genetic Diagnostic Methods for Detection for Novel Coronavirus 2019(nCoV-2019) in Japan

Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study

Analytical comparisons of SARS-COV-2 detection by qRT-PCR and ddPCR with multiple primer/probe sets

ddPCR: a more accurate tool for SARS-CoV-2 detection in low viral load specimens

Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis

The way to reduce the false negative results of 2019 novel coronavirus nucleic acid detection

Analysis of low positive rate of nucleic acid detection method used for diagnosis of novel coronavirus pneumonia

Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients

Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study

Two-step strategy for the identification of SARS-CoV-2 variant of concern 202012/01 and other variants with spike deletion H69-V70, France

Clinical Evaluation of Self-Collected Saliva by Quantitative Reverse Transcription-PCR (RT-qPCR), Direct RT-qPCR, Reverse Transcription-Loop-Mediated Isothermal Amplification, and a Rapid Antigen Test To Diagnose COVID-19

Lass-Florl C. Development and Validation of a Rapid, Single-Step Reverse Transcriptase Loop-Mediated Isothermal Amplification (RT-LAMP) System Potentially to Be Used for Reliable and High-Throughput Screening of COVID-19

Development of Reverse Transcription Loop-Mediated Isothermal Amplification Assays Targeting Severe Acute Respiratory Syndrome Coronavirus

RT-LAMP for rapid diagnosis of coronavirus SARS-CoV-2

Rapid and visual detection of 2019 novel coronavirus (SARS-CoV-2) by a reverse transcription loop-mediated isothermal amplification assay

Rapid Detection of COVID-19 Coronavirus Using a Reverse Transcriptional Loop-Mediated Isothermal Amplification (RT-LAMP) Diagnostic Platform

Alert to Potential Contagiousness: A Case of Lung Cancer With Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Selective Naked-Eye Detection of SARS-CoV-2 Mediated by N Gene Targeted Antisense Oligonucleotide Capped Plasmonic Nanoparticles

Multiplex reverse transcription loop-mediated isothermal amplification combined with nanoparticle-based lateral flow biosensor for the diagnosis of COVID-19

First Rapid Multiplex PCR Commercial Assay for SARS-CoV-2 Detection

Comparison of Abbott ID Now, DiaSorin Simplexa, and CDC FDA Emergency Use Authorization Methods for the Detection of SARS-CoV-2 from Nasopharyngeal and Nasal Swabs from Individuals Diagnosed with COVID-19

Clinical Evaluation of Three Sample-to-Answer Platforms for Detection of SARS-CoV-2

Multi-center evaluation of cepheid xpert(R) xpress SARS-CoV-2 point-of-care test during the SARS-CoV-2 pandemic

Positive rate of RT-PCR detection of SARS-CoV-2 infection in 4880 cases from one hospital in

Antibody detection assays for COVID-19 diagnosis: an early overview

The diagnostic value of joint detection of serum IgM and IgG antibodies to 2019•nCoV in 2019•nCoV infection

Serum IgA, IgM, and IgG responses in COVID-19

Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019

Preliminary study of serum 2019•nCoV IgM and IgG antibodies in the diagnosis of COVID•19

Reasons and solutions for "false positive results" of 2019 novel coronavirus•specific antibodies detection

Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients

Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections

Evaluation of Nucleocapsid and Spike Protein-Based Enzyme-Linked Immunosorbent Assays for Detecting Antibodies against SARS-CoV-2

SARS-CoV-2 antigen-detecting rapid diagnostic tests: an implementation guide

Evaluation of a novel antigen-based rapid detection test for the diagnosis of SARS-CoV-2 in respiratory samples

Low performance of rapid antigen detection test as frontline testing for COVID-19 diagnosis

Development of a Portable, Ultra-Rapid and Ultra-Sensitive Cell-Based Biosensor for the Direct Detection of the SARS-CoV-2 S1 Spike Protein Antigen

Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays.Interim guidance

WHO COVID-19: Case Definitions

［97］ National Health Commission & National Administration of Traditional Chinese Medicine. Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7)

COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention

Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province

Expressions of multiple inflammation markers in the patients with COVID•19 and their clinical values

Immune Phenotyping Based on the Neutrophil-to-Lymphocyte Ratio and IgG Level Predicts Disease Severity and Outcome for Patients With COVID-19

China Medical Treatment Expert Group for C. Clinical Characteristics of Coronavirus Disease 2019 in China

Association between platelet parameters and mortality in coronavirus disease 2019: Retrospective cohort study

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

Thrombocytopenia and its association with mortality in patients with COVID-19

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

Platelet-to-lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19

Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection

A Cytokine Circus with a Viral Ringleader: SARS-CoV-2-Associated Cytokine Storm Syndromes

Serum Amyloid A is a biomarker of severe Coronavirus Disease and poor prognosis

Clinical significance of serum hs-CRP, IL-6, and PCT in diagnosis and prognosis of patients with COVID-19

Serum Amyloid A Protein as a useful biomarker to predict COVID-19 patients severity and prognosis

Intrapulmonary activation of the angiotensin-converting enzyme type 2/angiotensin 1-7/G-protein-coupled Mas receptor axis attenuates pulmonary hypertension in Ren-2 transgenic rats exposed to chronic hypoxia

Circulating plasma levels of angiotensin II and aldosterone in patients with coronavirus disease 2019 (COVID-19): A preliminary report

Plasma ACE2 and risk of death or cardiometabolic diseases: a case-cohort analysis

Elevated plasma angiotensin converting enzyme 2 activity is an independent predictor of major adverse cardiac events in patients with obstructive coronary artery disease

Understanding the renin-angiotensin-aldosterone-SARS-CoV axis: a comprehensive review